

Rodrigo Ramella Munhoz, MD.



Rodrigo Ramella Munhoz, MD

PROFESSOR

Immunotherapy, Physiopathology and management of common side effects

Director of medical oncology fellowship program and specialist in immunotherapy at Sirio Libanes Hospital in Sao Paulo- Brazil. Attending in the Oncology Center and Melanoma and Sarcoma Group at Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Brazil. He is member of Brazilian Society of Clinical Oncology - SBOC, Grupo Brasileiro de Melanoma, American Society of Clinical Oncology – ASCO. His scientific interest and current research area are advanced cutaneous squamous cell carcinoma, Study of the Anti-PD1 Antibody PDR001, An Investigational Immunotherapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915), BRAFv600 mutation-positive, Metastatic Soft Tissue Sarcoma. Author and co-author of several publications in prestigious journals.

Full name: Rodrigo Ramella Munhoz

Country: Brazil

Current Position:

2013 – present Sarcoma and Melanoma Group, Instituto do Cancer do Estado de São Paulo, Brazil

2015 – present Oncology Center and Coordinator of the Medical Oncology Fellowship Program, Sirio Libanes Hospital, Brazil.

Education:

2015 Advanced clinical fellowship, melanoma/sarcoma at Memorial Sloan Kettering Cancer Center, New York, U.S.A.

2013 Fellowship in medical oncology, Oncology Center at Sirio Libanes Hospital, Brazil

2010 Residence in internal medicine, Universidade Estadual de Campinas, Brazil.
2006 Medical School at Universidade Estadual de Campinas, Brazil

Experience:

2015 - 2017 Medical oncology fellowship program – Co-coordinator
Oncology Center, Sírio Libanés Hospital.
2015 Clinical fellowship at Sylvester Comprehensive Cancer Center
and Jackson Memorial Hospital.
2013 – 2014 Assistant attending, Oncology Center, Sírio Libanés Hospital
2010 – 2013 Fellows Representative, Hospital Sírio Libanês Fellowship
Commission
2012 Observer at Sylvester Comprehensive Cancer Center and Jackson
Memorial Hospital
2011 Observer at Neuro-Oncology Department, M.D. Anderson Cancer
Center

Scientific Publications:

Number of publications as author or co-author: 33

Book and chapters: 7

Recent scientific publications:

Loong HH, Blay JY, Munhoz RR. “International collaborations and regional challenges in providing specialized multidisciplinary sarcoma care”. Am Soc Clin Oncol Educ Book

Matos GDR, de Camargo VP, Munhoz RR, Castro Jr G. “Non-GIST soft tissue sarcomas: an update”. E Cancer medical science; 13: 958

Oliveira LJC, Gongora ABL, Barbosa FG, Dos Anjos CH, Munhoz RR. “Atypical response with bone pseudo progresion in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma”. J Immunother Cancer 2018; 6(1): 130.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi AP, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku P, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu W, Scoyler RA, Messina J, Cochran AJ, Long GV, Ribas A. “High response rate to PD-1 blockade in desmoplastic melanomas”. Nature 2018;553: 347–350

Ribeiro MFSA, Sousa MC, Hanna SA, Maldaum MVC, Kurimori CO, Lima LGCA, Mattedi RL, Munhoz RR. “Tumor reduction with pazopanib in a patient with recurrent lumbar chordoma”. Case Rep Oncol Med 2018; Accepted for publication.

Espíndola LMD, Salhab RM, Dos Anjos C, Garicochea B, Munhoz RR. “Is it better to use ipilimumab combined with a PD-1 inhibitor or PD-1 inhibitor alone as initial immunotherapy in patients with metastatic melanoma?” Clin Skin Cancer, 2017; 2: 10-17

Munhoz RR, Tap WD, D’Angelo SP. “Development of checkpoint inhibitors for sarcomas”. Oncology & Hematology Review, 2017; 13(1): 26-9.

Rego JFM, Medeiros RSS, Braghiroli MI, Galvão B, Bezerra-Neto JE, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, Castro Jr G, Hoff PM, Rocha-Filho D, Costa FP, Riechelmann R. "Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer." *E Cancer* 2017; 11:767.

SBOC Working Group. "*Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors*". *Braz J Oncol* 2017; 13(43):1-8.

Chudgar NP, Brennan MF, Munhoz RR, Bucciarelli PR, Tan KS, D'Angelo SP, Bains M, Bott, Huang J, Park BJ, Rusch VW, Adusumilli OS, Tap WD, Singer S, Jones DR. "Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma". *J Thorac Cardiovasc Surg* 2017; 154(1):319-330.